Abstract：
OBJECTIVE: This study aims to explore the efficacy and safety of tirzepatide for patients with type 2 diabetes (T2D).
METHODS: Using specific keywords, we comprehensively go through the potential articles on Europe PMC, Scopus, PubMed, and ClinicalTrials.gov sources until July 12th, 2022. We collected all clinical trials that compare tirzepatide 5, 10, or 15 mg once-weekly with placebo or other glucose lowering agents in adult patients with T2D.
RESULTS: Nine clinical trials were included. Our pooled analysis revealed the dose-dependent superiority of tirzepatide in reducing HbA1c, ranging from -1.50% with 5 mg to -1.80% with 15 mg when compared with placebo, -0.61% with 5 mg to -0.95% with 15 mg when compared with GLP-1 receptor agonist, and -0.70% with 5 mg to 1.09% with 15 mg when compared with basal insulin. The dose-dependent superiority of tirzepatide was also seen in the bodyweight reduction effect with all comparators. These superiorities were not accompanied by increased odds of hypoglycemia, but there is an increase in gastrointestinal adverse events incidence.
CONCLUSIONS: Tirzepatide has shown superiority in glycemic control and bodyweight reduction with a good safety profile in patients with T2D. Tirzepatide may become a future potential drug in the management of T2D.
METHODS: Using specific keywords, we comprehensively go through the potential articles on Europe PMC, Scopus, PubMed, and ClinicalTrials.gov sources until July 12th, 2022. We collected all clinical trials that compare tirzepatide 5, 10, or 15 mg once-weekly with placebo or other glucose lowering agents in adult patients with T2D.
RESULTS: Nine clinical trials were included. Our pooled analysis revealed the dose-dependent superiority of tirzepatide in reducing HbA1c, ranging from -1.50% with 5 mg to -1.80% with 15 mg when compared with placebo, -0.61% with 5 mg to -0.95% with 15 mg when compared with GLP-1 receptor agonist, and -0.70% with 5 mg to 1.09% with 15 mg when compared with basal insulin. The dose-dependent superiority of tirzepatide was also seen in the bodyweight reduction effect with all comparators. These superiorities were not accompanied by increased odds of hypoglycemia, but there is an increase in gastrointestinal adverse events incidence.
CONCLUSIONS: Tirzepatide has shown superiority in glycemic control and bodyweight reduction with a good safety profile in patients with T2D. Tirzepatide may become a future potential drug in the management of T2D.
摘要：
目的：本研究旨在探讨替拉肽对2型糖尿病（T2D）患者的疗效和安全性。
方法：使用特定的关键字，我们全面浏览了欧洲PMC的潜在文章，Scopus,PubMed,和ClinicalTrials.gov来源，直到7月12日，2022年。我们收集了所有临床试验，这些临床试验比较了T2D成年患者中每周一次的替瑞沙肽5、10或15mg与安慰剂或其他降糖药物。
结果：纳入了9项临床试验。我们的汇总分析显示，在降低HbA1c方面，替拉肽具有剂量依赖性优势，与安慰剂相比，从5毫克的-1.50％到15毫克的-1.80％，与GLP-1受体激动剂相比，5mg-0.61%至15mg-0.95%，与基础胰岛素相比，5mg为-0.70％，15mg为1.09％。在所有比较者的体重减轻效果中也观察到了替利西帕肽的剂量依赖性优势。这些优势并没有伴随低血糖的几率增加，但胃肠道不良事件发生率增加。
结论：Tirzepatide在T2D患者的血糖控制和体重降低方面具有优势，且具有良好的安全性。Tirzepatide可能成为T2D治疗的潜在药物。
方法：使用特定的关键字，我们全面浏览了欧洲PMC的潜在文章，Scopus,PubMed,和ClinicalTrials.gov来源，直到7月12日，2022年。我们收集了所有临床试验，这些临床试验比较了T2D成年患者中每周一次的替瑞沙肽5、10或15mg与安慰剂或其他降糖药物。
结果：纳入了9项临床试验。我们的汇总分析显示，在降低HbA1c方面，替拉肽具有剂量依赖性优势，与安慰剂相比，从5毫克的-1.50％到15毫克的-1.80％，与GLP-1受体激动剂相比，5mg-0.61%至15mg-0.95%，与基础胰岛素相比，5mg为-0.70％，15mg为1.09％。在所有比较者的体重减轻效果中也观察到了替利西帕肽的剂量依赖性优势。这些优势并没有伴随低血糖的几率增加，但胃肠道不良事件发生率增加。
结论：Tirzepatide在T2D患者的血糖控制和体重降低方面具有优势，且具有良好的安全性。Tirzepatide可能成为T2D治疗的潜在药物。
